Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

dc.contributor.author	Pérez Encinas, Manuel Mateo
dc.date.accessioned	2017-06-07T07:07:56Z
dc.date.available	2017-06-07T07:07:56Z
dc.date.issued	2015
dc.identifier.issn	2045-7634
dc.identifier.uri	http://hdl.handle.net/20.500.11940/2944
dc.language.iso	eng
dc.title	Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months
dc.type	Artigo	es
dc.authorsophos	Casado, L. F.
dc.authorsophos	Garcia-Gutierrez, J. V.
dc.authorsophos	Massague, I.
dc.authorsophos	Giraldo, P.
dc.authorsophos	Perez-Encinas, M.
dc.authorsophos	de Paz, R.
dc.authorsophos	Martinez-Lopez, J.
dc.authorsophos	Bautista, G.
dc.authorsophos	Osorio, S.
dc.authorsophos	Requena, M. J.
dc.authorsophos	Palomera, L.
dc.authorsophos	Penarrubia, M. J.
dc.authorsophos	Calle, C.
dc.authorsophos	Hernandez-Rivas, J. A.
dc.authorsophos	Burgaleta, C.
dc.authorsophos	Maestro, B.
dc.authorsophos	Garcia-Ormena, N.
dc.authorsophos	Steegmann, J. L.
dc.identifier.doi	10.1002/cam4.440
dc.identifier.isi	357899100005
dc.identifier.pmid	25756742
dc.identifier.sophos	18584
dc.issue.number	7
dc.organization	Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago - Complexo Hospitalario Universitario de Santiago::Hematoloxía clínica
dc.page.initial	995
dc.page.final	1002
dc.rights.accessRights	openAccess
dc.typesophos	Artículo Original
dc.volume.number	4

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.